The p85β regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells

References

• Donahue AC, Fruman DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol 2004; 5: 183–197
   Google Scholar
• Fruman DA, Satterthwaite AB, Witte ON. Xid-like phenotypes: A B cell signalosome takes shape. Immunity 2000; 13: 1–3
   PubMedGoogle Scholar
• Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85. Science 1999; 283: 393–397
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: Comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006; 107: 642–650
   PubMed Web of Science ®Google Scholar
• Shi J, Cinek T, Truitt KE, Imboden JB. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocks antigen-mediated, but not CD3 monoclonal antibody-induced, activation of murine CD4+T cells. J Immunol 1997; 158: 4688–4695
   PubMedGoogle Scholar
• Deane JA, Fruman DA. Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol 2004; 22: 563–598
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535–602
   PubMed Web of Science ®Google Scholar
• Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. Binding of Ras to phosphoinositide 3-kinase p110alpha is required for Ras- driven tumorigenesis in mice. Cell 2007; 129: 957–968
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Aleman JO, Ueki K, Luo J, Asano T, Kaneto H, Stephanopoulos G, Cantley LC, Kahn CR. The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. Mol Cell Biol 2007; 27: 2830–2840
   PubMedGoogle Scholar
• Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194–204
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, Vanhaesebroeck B. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 2006; 177: 5122–5128
   PubMed Web of Science ®Google Scholar
• Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E, Rowan WC, Sancho S, Walker LS, Vanhaesebroeck B, Okkenhaug K. Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006; 177: 6598–6602
   PubMed Web of Science ®Google Scholar
• Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 2007; 109: 2894–2902
   PubMed Web of Science ®Google Scholar
• Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci USA 2006; 103: 16882–16887
   PubMed Web of Science ®Google Scholar
• Deane JA, Fruman DA. Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol 2004; 22: 563–598
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJH, Vanhaesebroeck B. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031–1034
   PubMed Web of Science ®Google Scholar
• Glassford J, Soeiro I, Skarell SM, Banerji L, Holman M, Klaus GG, Kadowaki T, Koyasu S, Lam EW. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene 2003; 22: 2248–2259
   PubMed Web of Science ®Google Scholar
• Suzuki H, Matsuda S, Terauchi Y, Fujiwara M, Ohteki T, Asano T, Behrens TW, Kouro T, Takatsu K, Kadowaki T, Koyasu S. PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction. Nat Immunol 2003; 4: 280–286
   PubMed Web of Science ®Google Scholar
• Suzuki H, Terauchi Y, Fujiwara M, Aizawa S, Yazaki Y, Kadowaki T, Koyasu S. Xid-like immunodeficiency in mice with disruption of the p85 subunit of phosphoinositide 3-kinase. Science 1999; 283: 390–392
   PubMed Web of Science ®Google Scholar
• Donahue AC, Hess KL, Ng KL, Fruman DA. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. Int Immunol 2004; 16: 1789–1798
   PubMedGoogle Scholar
• Glassford J, Vigorito E, Soeiro I, Madureira PA, Zoumpoulidou G, Brosens JJ, Turner M, Lam EW. Phosphatidylinositol 3-kinase is required for the transcriptional activation of cyclin D2 in BCR activated primary mouse B lymphocytes. Eur J Immunol 2005; 35: 2748–2761
   PubMedGoogle Scholar
• Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman DA. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. Eur J Immunol 2004; 34: 2968–2976
   PubMedGoogle Scholar
• Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85{beta} subunit of phosphoinositide 3-kinase. J Immunol 2004; 172: 6615–6625
   PubMed Web of Science ®Google Scholar
• Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 2005; 25: 2593–2606
   PubMed Web of Science ®Google Scholar
• Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, Depinho RA, Izumo S, Cantley LC. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005; 25: 9491–9502
   PubMedGoogle Scholar
• Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 1997; 25: 1317–1318
   PubMed Web of Science ®Google Scholar
• Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Ig[alpha]/[beta] heterodimer. Cell 2004; 117: 787–800
   PubMed Web of Science ®Google Scholar
• Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 2007; 109: 2894–2902
   PubMed Web of Science ®Google Scholar
• Pasparakis M, Schmidt-Supprian M, Rajewsky K. I{kappa}B kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002; 196: 743–752
   PubMed Web of Science ®Google Scholar
• Donahue AC, Kharas MG, Fruman DA. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Meth Enzymol 2007; 434: 131–154
   PubMed Web of Science ®Google Scholar
• Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 2004; 15: 147–159
   PubMedGoogle Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471–484
   PubMed Web of Science ®Google Scholar
• Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol 2007; 37: 2923–2936
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Ali K, Vanhaesebroeck B. Antigen receptor signalling: A distinctive role for the p110delta isoform of PI3K. Trends Immunol 2007; 28: 80–87
   PubMed Web of Science ®Google Scholar
• Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: Partners in crime in inflammation in rheumatoid arthritis and beyond?. Nat Rev Immunol 2007; 7: 191–201
   PubMed Web of Science ®Google Scholar
• Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: Towards an ‘aspirin of the 21st century’?. Nat Rev Drug Discov 2006; 5: 903–918
   PubMed Web of Science ®Google Scholar
• Fukao T, Yamada T, Tanabe M, Terauchi Y, Ota T, Takayama T, Asano T, Takeuchi T, Kadowaki T, Hata Ji J, Koyasu S. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol 2002; 3: 295–304
   PubMedGoogle Scholar
• Lu-Kuo JM, Fruman DA, Joyal DM, Cantley LC, Katz HR. Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. J Biol Chem 2000; 275: 6022–6029
   PubMedGoogle Scholar
• Woodland RT, Schmidt MR, Thompson CB. BLyS and B cell homeostasis. Semin Immunol 2006; 18: 318–326
   PubMed Web of Science ®Google Scholar
• Matheu MP, Deane JA, Parker I, Fruman DA, Cahalan MD. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. J Immunol 2007; 179: 2261–2269
   PubMedGoogle Scholar
• Jacob A, Cooney D, Pradhan M, Coggeshall KM. Convergence of signaling pathways on the activation of ERK in B cells. J Biol Chem 2002; 277: 23420–23426
   PubMedGoogle Scholar
• Chamberlain MD, Berry TR, Pastor MC, Anderson DH. The p85alpha subunit of phosphatidylinositol 3′-kinase binds to and stimulates the GTPase activity of Rab proteins. J Biol Chem 2004; 279: 48607–48614
   PubMed Web of Science ®Google Scholar
• Kang H, Schneider H, Rudd CE. Phosphatidylinositol 3-kinase p85 adaptor function in T-cells. Co-stimulation and regulation of cytokine transcription independent of associated p110. J Biol Chem 2002; 277: 912–921
   PubMedGoogle Scholar
• Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2002; 99: 419–424
   PubMed Web of Science ®Google Scholar